Startseite>>Signaling Pathways>> Endocrinology and Hormones>> Glucocorticoids & Mineralocorticoids>>Cortistatin-29 (rat) (trifluoroacetate salt)

Cortistatin-29 (rat) (trifluoroacetate salt)

Katalog-Nr.GC43313

Cortistatin-29 is a neuropeptide that is structurally similar to somatostatin-28.

Products are for research use only. Not for human use. We do not sell to patients.

Cortistatin-29 (rat) (trifluoroacetate salt) Chemische Struktur

Cas No.: 1815618-17-7

Größe Preis Lagerbestand Menge
500μg
341,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Cortistatin-29 is a neuropeptide that is structurally similar to somatostatin-28. It is produced by cleavage of preprocortistatin to procortistatin, which is cleaved at dibasic amino acids to form cortistatin-29 and cortistatin-14 as well as other partial cleavage products. Cortistatin mRNA is expressed in the human brain and in interneurons of the rat hippocampus and cerebral cortex. Cortistatin-29 binds to somatostatin (SST) receptors with IC50 values of 2.8, 7.1, 0.2, 3, and 13.7 nM for SST1-5, respectively. Cortistatin-29 is found at similar levels as cortistatin-14 in mouse AtT20 cells but is secreted at a lower level. Cortistatin-29 corresponds to residues 85-112 of the rat peptide sequence.

Bewertungen

Review for Cortistatin-29 (rat) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cortistatin-29 (rat) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.